Altimmune Reports Positive Phase 2 RECLAIM Results for Pemvidutide in Alcohol Use Disorder
GAITHERSBURG, Md., July 28, 2026 Altimmune, Inc. announced positive topline results from its Phase 2 RECLAIM clinical trial evaluating...
GLP-1
Advertisement
Antag Therapeutics Doses First Patient in Phase 2a Trial of AT7687
COPENHAGEN, Denmark, July 28, 2026 Antag Therapeutics announced that the first patient has been dosed in its Phase 2a...
Veru Completes Enrollment in Phase 2b PLATEAU Obesity Trial
MIAMI, Fla., July 27, 2026 Veru Inc. announced the successful completion of patient enrollment in its Phase 2b PLATEAU...
Eli Lilly Reports Positive Phase 3 Retatrutide Results
INDIANAPOLIS, July 23, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3 TRIUMPH-2 and...
Samsung Biologics to Acquire PolyPeptide for CHF 1.46B
INCHEON, South Korea, July 20, 2026 Samsung Biologics has announced a landmark all-cash public tender offer to acquire 100%...
Advertisements
Novo Nordisk Secures EU Approval for Oral Wegovy
BAGSVÆRD, Denmark, July 15, 2026 Novo Nordisk has achieved a major regulatory milestone after the European Commission (EC) granted...
Boehringer Ingelheim Advances BI 3034701 into Phase II Obesity Trial
INGELHEIM, Germany, July 16, 2026 Boehringer Ingelheim has initiated a Phase II clinical trial evaluating BI 3034701, an investigational...
MetaVia Advances DA-1726 Phase 1 Obesity Trial
CAMBRIDGE, Mass. | July 9, 2026 MetaVia Inc., a clinical-stage biotechnology company focused on developing innovative therapies for cardiometabolic...
Rani Therapeutics Expands Obesity Pipeline With PegBio
SAN JOSE, Calif. | July 9, 2026 Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company pioneering oral biologic drug...
Helix Expands Drug Discovery Collaboration with AstraZeneca
SAN MATEO, Calif., July 7, 2026 Helix has announced a multi-year strategic agreement with AstraZeneca to accelerate genomic research,...
Advertisement
